TerSera Therapeutics to sponsor “NET Cancer Health Storylines” by Alira Health and Carcinoid Cancer Foundation to support patients suffering from Carcinoid Syndrome Diarrhea

News
Published on:
January 23, 2023

We are pleased to announce TerSera Therapeutics’ sponsorship with the Carcinoid Cancer Foundation (CCF) and Alira Health to expand and optimize a holistic patient journey digital platform for patients with Neuroendocrine Tumors and Carcinoid Syndrome.

This patient support program is a powerful collaboration between TerSera Therapeutics, Carcinoid Cancer Foundation, and Alira Health. We are excited for Health Storylines to power this high-touch, high-tech, and high-science support for patients with NET Cancer and Carcinoid Syndrome."
Jennifer Lannon Director, Partnerships and Business Development, Patient Advocacy, Alira Health

To support patients in coping with the impact NETs have on their quality of life and collaborate with their care team on treatment decisions, Alira Health and the Carcinoid Cancer Foundation have collaborated since 2015 to build “NET Cancer Health Storylines,” a customized version of the Health Storylines™ app that makes it easy for patients to record their symptoms, nutritional concerns, moods, medication and more. The NET Health Storylines app provides patients with resources developed by NET experts. Specific tools include a Stool Diary, NET Nutrition tool, Medication tracker, and additional educational resources. The app is available for download at the NET Cancer Health Storylines website or through the Apple App Store or Google Play.

“We are grateful for this support from TerSera to continue to enhance the NET Health Storylines platform to distribute meaningful educational content to NETs patients. The resources available through this platform are important tools in supporting NET patients throughout their journey,” said Keith Warner, Chief Executive Officer of the Carcinoid Cancer Foundation.

“Collaborating with CCF and the NET Cancer Health Storylines platform is a fantastic opportunity for us to support patients with Carcinoid Syndrome Diarrhea beyond our existing clinical nurse educator program. We are also looking forward to learning from patients how we can continue to support them better on their journey,” said Pamela Gaytan, Executive Director, Clinical Nurse Educators and Patient Advocacy of TerSera Therapeutics.

“This patient support program is a powerful collaboration between TerSera Therapeutics, Carcinoid Cancer Foundation, and Alira Health. We are excited for Health Storylines to power this high-touch, high-tech, and high-science support for patients with NET Cancer and Carcinoid Syndrome,” adds Jennifer Lannon, Director, Partnerships & Business Development, Patient Advocacy of Alira Health.

About Alira Health

Alira Health is a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance. From development to medical care, Alira Health complements the expertise of its Pharma, Biotech, and MedTech clients with a full spectrum of services across their entire solutions lifecycle.

About TerSera Therapeutics

TerSera Therapeutics acquires, develops, and markets specialty pharmaceutical products with a focus on oncology and non-opioid pain. Its mission is to provide products which truly make a difference for patients. For more information about TerSera Therapeutics, please visit www.tersera.com.

About Carcinoid Cancer Foundation

The Carcinoid Cancer Foundation is the oldest nonprofit carcinoid and neuroendocrine cancer organization in the United States, founded in 1968. The mission of the foundation is to increase awareness and educate the general public and healthcare professionals regarding neuroendocrine tumors (NETs), to support NET cancer patients and their families, and to serve as patient advocates. Visit the CCF website for more information, www.carcinoid.org.

Related news

Multimedia November 28, 2023
How to Accelerate Lupus Solutions with RWD
Explore lupus solutions and real-world treatment impacts through a discussion on patient aspects and the role of technology in streamlining research efficiency.
Lupus Patient Centricity Real-World Evidence (RWE)
Blog November 17, 2023
Misconceptions About Patient-Centric Co-Design
Many people have misconceptions about patient-centric co-design, and these misconceptions are holding companies back.
Co-Design Digital Health MedTech Patient Centricity Pharma
Events November 8, 2023
Spain Healthcare Innovation Summit
We will sponsor and speak at Spain Healthcare Innovation Summit, a premier event that brings together healthcare professionals from across Spain and beyond to discuss the latest developments(...)
Market Access Patient Centricity Spain
News November 6, 2023
Alira Health and FORWARD Launch Enhanced Lupus Patient Registry, Accelerating Solutions for Patients
Alira Health and FORWARD announced the launch of the enhanced Lupus Registry, enabling patients, caregivers, and research sponsors to gain better insights, and achieve better patient outcomes.
Patient Advocacy Patient Centricity Registry-based studies
Case Studies October 26, 2023
Pharma Develops e-Health Solution That Prioritizes Patients’ True Unmet Needs
A leading pharma company in the respiratory market sought support developing the right digital platform to expand their patient base and increase retention.
Digital Health Digital Therapeutics
Blog October 16, 2023
How to Co-Design a Solution with Patients to Meet Their Needs
To learn how you can benefit from a co-design approach and how to get started, we spoke with two experts on patient engagement and co-design.
Digital Health MedTech Patient Centricity Patient Engagement Pharma
Multimedia October 2, 2023
MedTech World: Interview with Gabriele Brambilla, Season 2
Gabriele Brambilla returned to the MedTech World Podcast to discuss the power the CARES Act gives patients over their digital health data. 
Digital Health MedTech
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.